FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents an oral tableted pharmaceutical composition used for oral administration and containing dexamethasone as an active ingredient, and the excipients: lactose, povidone, magnesium stearate, and differing by the fact that additionally contains the excipients: croscarmellose sodium, microcrystalline cellulose; lactose is lactose monohydrate with the ingredients taken in certain proportions, mg per one tablet.
EFFECT: invention provides high transportation durability and storage stability, and also enables reducing a number of tablets taken and side effects caused by prolonged treatment.
2 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TABLETS OF ULIPRISTAL ACETATE | 2009 |
|
RU2492853C2 |
| PHARMACEUTICAL COMPOSITION IN FORM OF TABLET AND METHOD OF OBTAINING THEREOF | 2014 |
|
RU2546002C1 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN FORM OF DISPERSIBLE TABLET CONTAINING GRANULATED ISONIAZID AND GRANULATED RIFAPENTINE, AND METHOD FOR PREPARING IT | 2014 |
|
RU2694056C2 |
| PREPARATION FOR TREATING ANEMIA ASSOCIATED WITH A CHRONIC RENAL DISEASE AND METHOD FOR PRODUCTION THEREOF | 2020 |
|
RU2756312C1 |
| ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET COMPRISING GRANULES OF ISONIAZID AND GRANULES OF RIFAPENTINE AND ITS PROCESS OF PREPARATION | 2014 |
|
RU2682178C2 |
| PHARMACEUTICAL ANTIDIABETIC COMPOSITION | 2010 |
|
RU2445963C2 |
| PHARMACEUTICAL FORMULATIONS OF HIF HYDROXYLASE INHIBITORS | 2014 |
|
RU2681304C2 |
| PHARMACEUTICAL COMPOSITIONS OF MONTELUCAST AND LEVOCETIRISINE | 2013 |
|
RU2677649C2 |
| PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINED FORMULATION CONTAINING A GLUCOKINASE ACTIVATOR AND AN SGLT-2 INHIBITOR, AND METHODS FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2770043C1 |
